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Abdominal subcutaneous adipose tissue insulin resistance
and lipolysis in patients with non-alcoholic steatohepatitis
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Background: Systemic insulin resistance (IR) is a primary feature in non-alcoholic steatohepatitis (NASH), however, there remain limited data
on tissue-speciﬁc insulin sensitivity in vivo.
Methods: We examined tissue-speciﬁc (adipose, muscle and liver) insulin sensitivity and inﬂammation in 16 European Caucasian patients
with biopsy-conﬁrmed NASH and in 15 healthy controls. All underwent a two-step hyperinsulinaemic euglycaemic clamp incorporating stable
isotope measurements of carbohydrate and lipid metabolism with concomitant subcutaneous adipose tissue (SAT) microdialysis.
Results: Hepatic and muscle insulin sensitivity were decreased in patients with NASH compared with controls, as demonstrated by reduced
suppression of hepatic glucose production and glucose disposal (Gd) rates following insulin infusion. In addition, rates of lipolysis were higher
in NASH patients with impaired insulin-mediated suppression of free fatty acid levels. At a tissue speciﬁc level, abdominal SAT in patients with
NASH was severely insulin resistant, requiring >sixfold more insulin to cause 1/2-maximal suppression of glycerol release when compared with
healthy controls. Furthermore, patients with NASH had signiﬁcantly higher circulating levels of pro-inﬂammatory adipocytokines than controls.
Conclusion: NASH patients have profound IR in the liver, muscle and in particular adipose tissues. This study represents the ﬁrst in vivo
description of dysfunctional SAT in patients with NASH.
Keywords: adipose tissue, fatty liver, insulin sensitivity, lipolysis, steatohepatitis
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is reaching epidemic
proportions, affecting up to 30% of the general population
and 70–90% of individuals with type 2 diabetes and/or
obesity [1], and is now expected to become the leading
indication for liver transplantation by 2020 [2]. Furthermore,
NAFLD and in particular the inflammatory (with or without
fibrosis) component of non-alcoholic steatohepatitis (NASH),
is associated with a significant risk of developing type 2 diabetes,
chronic kidney disease, and cardiovascular morbidity and
death [1,3]. A better understanding of the key components
of the pathogenesis of NASH is therefore needed to provide
new therapeutic approaches and thus prevent progressive liver
disease and extra-hepatic complications.
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Systemic insulin resistance (IR) is recognized as one
of the main pathogenic factors in NASH [4,5]. Using
hyperinsulinaemic euglycaemic clamp techniques (coupled
with stable isotopes), several studies have identified the
liver (with increased glucose production) and muscle [with
decreased glucose disposal (Gd)] as the key sites of increased IR
in patients with NASH [5–9]. Recent studies have recognized
the importance of adipose tissue, as the principal source of
fatty acids (≈60%) for the liver, in driving lipid synthesis in
both healthy individuals [10] and NASH patients [11]. Adipose
tissue is a highly insulin responsive tissue. In an insulin-sensitive
state, insulin promotes lipid storage [through fatty acid uptake,
re-esterification and de novo lipogenesis (DNL)] and inhibits
triglyceride lipolysis, the process whereby triglycerides are
hydrolysed to release non-esterified fatty acids (NEFAs) from
their glycerol backbone. Studies in patients with NASH have
inferred changes in adipose tissue insulin sensitivity through
systemic measures of circulating NEFA which are elevated in
both the fasting state and under hyperinsulinaemic conditions
[6–8,12]. Importantly, this appears to be independent of the
degree of obesity [13].
Adipose tissue dysfunction is considered to be a major
contributory factor of NASH, by means of the resultant
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‘lipotoxicity’ inducing both hepatic IR and skeletal muscle IR
[14]. Studies that have been published to date have, however,
solely focused on quantifying whole-body lipolysis using either
circulating NEFA [i.e. quantified by adipose insulin resistance
(ADIPO-IR) index = fasting NEFA × insulin] [8,9,12] or the
rate of systemic appearance of labelled glycerol/palmitate
isotopes [6,13,15]. In particular, no studies have assessed
the response of local adipose tissue to the action of insulin,
which provides greater insights into the functional relevance
of adipose tissue. A greater understanding of which adipose
depots are dysfunctional in NASH patients would greatly
enhance our knowledge in developing new targeted therapies.
Traditionally, visceral adipose tissue (VAT) has been recognized
as a major contributor to IR and metabolic conditions including
NASH, due to its close proximity to the portal vein and
abundance of pro-inflammatory mediators [16,17]. However,
as VAT only contributes to 15–20% of circulating NEFA
pool [18,19], researchers have questioned whether overspill
from abdominal subcutaneous adipose tissue (SAT) plays a
more significant role. Indeed, while several studies have linked
abdominal SAT with indices of IR in subjects with and without
metabolic syndrome [20–23], none have examined it in relation
to NASH.
Adopting an integrative physiological approach with
functional measures of lipid and carbohydrate flux, we
have performed a clinical study to determine the relative
contribution of tissue-specific insulin sensitivity, notably in
SAT, in patients with biopsy-proven NASH in comparison
with a healthy control cohort.
Research Design and Materials
The clinical protocols received full ethical approval from Leices-
tershire, Northamptonshire and Rutland (ref. 10/H0402/32)
and South Birmingham (ref. 10/H1207/15) Local Research
Ethics Committees. All adult subjects gave informed written
consent prior to participation.
Study Subjects
NASH Patients. Sixteen patients with a definitive diagnosis
of NASH on liver biopsy within 6 months of the study
were recruited. The histological diagnosis was made using
well-established criteria [24] by two independent liver
histopathologists. The subjects were of adult age (18–70 years)
and had a body mass index (BMI) ≥ 25 kg/m2. Patients with
co-existing type 2 diabetes were diet-controlled or were on
a stable dose of metformin ± gliclazide for a minimum of
3 months prior to the study and had a glycated haemoglobin
1c (HbA1c) < 9.0%. Participants were excluded if they had a
history of excess alcohol consumption (females >14 units/week
and males >21 units/week), liver disease of other aetiology,
decompensated cirrhosis (Child’s Pugh B or C), recent or
concomitant drug use of inducers of hepatic steatosis/weight-
inducing therapy, and significant active medical illnesses (with
the exception of type 2 diabetes). All patients with no previous
diagnosis of type 2 diabetes underwent a 75 g oral glucose
tolerance test (OGTT).
Healthy Volunteers. Fifteen healthy volunteers (9 males : 6
females; mean age 33 ± 2 years) were recruited by use
of a local advertisement. All controls were asymptomatic,
non-diabetic, were taking no regular medication and had
no significant medical history of note. Female controls
had pregnancy excluded and were not taking any form of
hormonal contraception. In the healthy control cohort, all
consumed alcohol within recommended limits, had normal
liver function tests (LFTs) and had normal levels of non-
invasive markers of hepatic injury (serum cytokeratin-18) and
fibrosis [serum enhanced liver test, enhanced liver fibrosis
(ELF)]. Furthermore, all controls had a negative NAFLD liver
fat score (<−0.640) and estimated liver fat <3.0% based on
the Kotronen et al. equations, which were originally validated
with 1H-magnetic resonance spectroscopy (MRS) [25]; 5 of 15
subjects underwent a hepatic MRS, as part of a separate study,
and in keeping with the Kotronen equations, had hepatic
steatosis excluded (<2.5%).
Study Design
All participants underwent a two-step hyperinsulinaemic eug-
lycaemic clamp incorporating stable isotopes with concomitant
SAT microdialysis at the NIHR/Wellcome Trust Clinical
Research Facility (WTCRF, Birmingham, UK) (Figure S1,
Supporting information).
HepaticDNL. At 17:00 hours, participants were admitted to the
WTCRF and total body water was estimated by bioimpedance
(Tanita BC418MA, Amsterdam, the Netherlands). A standard-
ized meal (carbohydrate 45 g, protein 23 g and fat 20 g) was
provided at 17:00 hours, after which participants remained
fasted until the end of the clamp at 14:00 hours the next day. To
determine rates of DNL, participants were given oral deuterated
water, 2H2O (3 g/kg total body water in two divided doses), at
18:00 and 22:00 hours followed by ad libitum drinking water
enriched with 0.4% 2H2o.
Two-Step Hyperinsulinaemic Euglycaemic Clamp. At 08:00
hours the next morning fasting blood samples were taken
by standard needle venepuncture prior to starting the two-
step hyperinsulinaemic euglycaemic clamp. Arterialized blood
was sampled to determine the blood glucose concentration
at which to maintain (‘clamp’) the participant throughout
the study using an YSI 2700 machine (YSI life sciences,
Fleet, Hampshire, UK). An intravenous bolus of U-[13C]-
glucose (2 mg/kg body weight; CK gas limited, Hook, UK) was
administered over 1 min followed by a constant infusion rate
(0.02 mg/kg/min) for 6 h until the end of the clamp. Steady
state blood samples were taken at three time points during
the final 30 min of the 2-h basal phase. At 10:00 hours, low-
dose insulin (Actrapid; Novo Nordisk, Copenhagen, Denmark)
was infused at 20 mU/m2/min. At 10:04 hours a concomitant
infusion of 20% glucose enriched with U-[13C]-glucose to 4%
was commenced. Arterialized blood samples were taken at
5 min intervals and the 20% glucose infusion rate was changed
to maintain fasting glycaemic levels. Steady state blood samples
were taken at three time points in the final 30 min of the
2-h low-dose insulin infusion. The insulin infusion rate was
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then increased to 100 mU/m2/min (high-dose) for 2 h with
sampling as described above. Rates of hepatic endogenous
glucose production (EGP) and Gd were calculated by using
modified versions of the Steele Equations [26,27].
Adipose Microdialysis. A microdialysis catheter (CMA micro-
dialysis AB, Solna, Sweden) was inserted after local anaesthetic
(5 ml 1% lignocaine) was injected into the abdominal SAT
(minimum depth 1 cm), 10 cm lateral to the umbilicus, prior
to commencing the clamp. Thereafter, micro-dialysate samples
were collected into micro-vials (0.3 μl/min) every 30 min until
the end of the clamp.
Data Collection and Analysis
Clinical and Biochemical Parameters. Participant demograph-
ics and clinical/biochemical measures were recorded at the
study visit. These included 75 g OGTT, anthropometry (includ-
ing bioimpedance), fasting haematological/biochemical bloods
and non-invasive serum markers of liver injury [cytokeratin-18
(CK-18), ELF test, Kotronen score)]. Serum insulin, NEFA and
adipocytokines [adiponectin, leptin, resistin, tumour necro-
sis factor alpha (TNF-α), high sensitivity C-reactive protein
(hs-CRP), interleukin-6 (IL-6), IL-17, chemokine ligand-2
(CCL-2), CCL-3, CCL-4 and CCL-5] were measured using
commercially available kits. Detailed descriptions of the above
are available in Appendix S1.
Abdominal SAT Microdialysis. Microdialysate samples were
analysed using a mobile photometric, enzyme-kinetic analyser
(CMA Iscus Flex) for glycerol concentration. The rate of
interstitial glycerol release represented the magnitude of SAT
lipolysis in the fasted state and in response to insulin.
Stable Isotope Mass Spectrometry Analysis. The enrichment
of U-[13C]-glucose in plasma was determined by gas
chromatography–mass spectrometry (model 5973; Agilent
technologies, Cheshire, UK). Deuterium enrichment of the
body water pool was measured using the Gasbench II
(www.thermo.com), an automated H2/H2O equilibration
device, coupled on-line to a ThermoFinnigan Deltaplus XP
Isotope Ratio Mass Spectrometer (IRMS; ThermoFinnigan
MAT GmbH, Bremen, Germany). The full methods have been
previously described in detail [28]. Deuterium enrichment
in the palmitate fraction of total plasma triglycerides
was measured on an automated GC/TC/IRMS system
(ThermoFinnigan Delta Pus XP; www.thermo.com).
Contribution of Hepatic DNL to Total Palmitate Synthesis.
The percentage contribution of hepatic DNL to endogenous
palmitate synthesis was determined by the incorporation of
2H2O in the palmitate present in the plasma total triglyceride
pool, as previously described [28]. This percentage was
calculated from the increase in the 2H/1H ratio in the
palmitate methylester of the total triglyceride fraction and
in the water of plasma samples taken before (17:00 hours, at
admission) and 14 h after the initial ingestion of the 2H2O
tracer (08:00 hours, before the start of the hyperinsulinaemic
euglycaemic clamp). The following formula was used: % hepatic
DNL contributes to endogenous palmitate synthesis = (delta
2H/1H ratio in palmitate methylester)/(delta 2H/1H ratio in
waterpool) × (34/22) × 100%. In the equation, 34 is the total
number of H-atoms in palmitate methylester and 22 is the
number of water molecules incorporated into palmitate via
DNL as observed in previous rodent studies [29] and currently
used in human studies [30].
Statistical Analysis
Descriptive statistics was applied to characterize the NASH and
healthy volunteer cohorts. Continuous clinical and laboratory
variables are reported as means and standard error (s.e.) as
all variables had parametric distribution on D’Agostino and
Pearson Omnibus Normality testing. Categorical variables are
reported as number and percentages. Area under the curve
(AUC) analysis was performed using the trapezoidal method for
interstitial glycerol release during the clamp. For comparison
of single variables, unpaired Student t-tests were used (or
non-parametric equivalents where data were not normally
distributed). Where repeated samples were taken repeated-
measures one-way analysis of variance (anova) was used,
incorporating the Dunnett’s test for multiple comparisons.
The significance level was set at p < 0.05. All analyses
were performed using the graphpad prism 5.0 software
package.
Results
Participant Characteristics
Participant demographics and clinical characteristics are
summarized in Table 1. NASH subjects were significantly
older (54.4 ± 2.1 vs. 33.1 ± 2.2 years; p < 0.0001) and had
a higher BMI (34.3 ± 1.0 vs. 26.7 ± 1.0 kg/m2; p < 0.0001)
and abdominal fat mass on bioimpedance (20.3 ± 1.5 vs.
12.0 ± 1.5 kg; p = 0.0011). Of the 16 subjects with NASH,
5 had mild-moderate fibrosis (Kleiner F1-F2) and 9 had
advanced fibrosis (F3-F4). NASH subjects had significantly
higher serum levels of liver enzymes [alanine transaminase
(ALT) 68.7 ± 11 vs. 18.9 ± 2.6 IU/l; p = 0.0001], serum CK-18
M30 levels (544 ± 116 vs. 161 ± 9.8 IU/l; p = 0.0034) and ELF
test (9.20 ± 0.3 vs. 7.34 ± 0.1; p < 0.001); values for all these
parameters were within accepted reference ranges in the healthy
volunteers.
Systemic IR
Fasting serum glucose, insulin and homeostatic model assess-
ment insulin resistance (HOMA-IR, 4.40 ± 0.8 vs. 1.19 ± 0.2)
were significantly higher in patients with NASH (all p < 0.001)
(Figure 1A, B). During the two-step hyperinsulinaemic clamp,
NASH subjects had significantly lower weight-adjusted glu-
cose infusion rates in response to low-dose (1.47 ± 0.08
vs. 3.08 ± 0.4 mg/kg/min; p = 0.0008) and high-dose insulin
(5.80 ± 0.4 vs. 9.14 ± 0.5 mg/kg/min; p < 0.0001). In keep-
ing with peripheral (largely muscle) IR, weight-adjusted Gd
rates were significantly lower in NASH subjects at low-dose
(0.85 ± 0.1 vs. 1.76 ± 0.4 mg/kg/min; p < 0.05) and high-
dose insulin infusions (4.55 ± 0.6 vs. 6.10 ± 0.5 mg/kg/min;
p = 0.05) (Figure 1C).
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Table 1. Demographics and clinical parameters of 16 patients with NASH and 15 healthy controls. Values are mean (s.e.), unless stated. All blood
parameters were fasting samples. Comparisons of continuous variables were made with unpaired Student’s t-test, and categorical variables with fisher
exact/chi-squared test.
NASH (n = 16) Controls (n = 15) p-Value
Demographics
Male sex, n (%) 11 (68.8) 9 (60.0) 0.716
Age (years) 54.4 (2.1) 33.1 (2.2) <0.0001
Ethnicity, n (%)
Caucasian 16 (100) 14 (93.3) 0.484
Asian 0 (0) 1 (6.7)
Metabolic parameters
Type 2 diabetes, n (%) 7 (43.8) 0 (0) 0.001
Impaired glucose tolerance, n (%) 3 (18.8) 0 (0)
Normal glucose tolerance, n (%) 6 (37.5) 15 (100)
Fasting glucose (mmol/l) 5.34 (0.24) 4.37 (0.067) 0.0008
Fasting insulin (pmol/l) 125.8 (20.8) 43.3 (7.41) 0.0003
HbA1c (%) 5.99 (0.21) — —
Pre-study OAD treatment, n (%) 8 (50.0) 0 (0) 0.0024
Pre-study statin treatment, n (%) 7 (43.8) 0 (0) 0.0068
Pre-study anti-hypertensive treatment, n (%) 6 (37.5) 0 (0) 0.0177
BMI (kg/m2) 34.3 (1.04) 26.7 (0.95) <0.0001
Weight (kg) 100.3 (3.83) 78.5 (3.67) 0.0003
Total fat mass (kg) 35.8 (2.64) 20.2 (1.79) <0.0001
Truncal fat mass (kg) 20.3 (1.45) 12.0 (1.51) 0.0011
Systolic BP (mmHg) 129.4 (3.43) 129.3 (2.74) 0.982
Waist circumference (cm) 114.1 (2.87) 85.9 (3.07) <0.0001
Total cholesterol (mmol/l) 4.51 (0.20) 4.59 (0.30) 0.891
HDL (mmol/l) 1.11 (0.064) 1.26 (0.11) 0.256
LDL (mmol/l) 3.01 (0.21) 2.73 (0.43) 0.550
Triglycerides (mmol/l) 1.95 (0.26) 1.62 (0.34) 0.438
TSH (μU/l) 2.76 (0.38) 2.01 (0.31) 0.165
Creatinine (μmol/l) 71.3 (3.46) 72.6 (3.47) 0.800
Liver parameters
AST (IU/l) 55.1 (5.66) 20.4 (1.55) <0.0001
ALT (IU/l) 68.7 (10.6) 18.9 (2.57) 0.0001
Alk Phos (IU/l) 155.7 (25.3) 128 (9.64) 0.327
Bilirubin (μmol/l) 13.4 (1.76) 12.0 (1.02) 0.494
Albumin (g/l) 47.1 (0.70) 41.6 (0.77) <0.001
Platelets (×109 l−1) 203.3 (14.7) 216.1 (10.5) 0.489
CK-18 M30 (IU/l) 543.4 (115.8) 160.9 (9.83) 0.0034
ELF test 9.20 (0.30) 7.34 (0.12) <0.0001
Histology parameters (NASH only)
Median Kleiner fibrosis score*(IQR) 3.0 (1.0–3.75) — —
Median NAFLD activity score†(IQR) 4.5 (4.0–5.0) — —
Bold are the p-values that are significant at <0.05. ALT, alanine transaminase; AST, aspartate transaminase; Alk phos, alkaline phosphatase; BMI, body
mass index; BP, blood pressure; CK-18, cytokeratin-18; ELF, enhanced liver fibrosis; HbA1c, glycated haemoglobin 1c; HDL, high-density lipoprotein; IQR,
interquartile range; LDL, low-density lipoprotein; NAFLD, Non-alcoholic fatty liver disease; NASH, non-alcoholic steatohepatitis; OAD, oral anti-diabetic
drug; TSH, thyroid stimulating hormone.
*The Kleiner fibrosis score ranges from 0 to 4, whereby 0 = no fibrosis and 4 = cirrhosis.
†The NAFLD activity score (scored out of 8) is a sum of steatosis (0–3), hepatocyte ballooning (0–2) and lobular inflammation (0–3).
Hepatic IR
Although fasting EGP rates were similar in patients with NASH
and healthy controls (2.14 ± 0.1 vs. 2.15 ± 0.1 mg/kg/min;
p > 0.9; Figure 1D), this was in the context of fasting hyper-
insulinaemia (Figure 1B, Table 1); changes were consistent
with hepatic IR. The hepatic IR index (= EGP × fasting insulin
[31]) was significantly higher in NASH patients (278 ± 52.7
vs. 90.0 ± 14.9 mg/kg/min pmol/ml; p = 0.0024). In addition,
low-dose insulin-mediated suppression of EGP was decreased
in patients with NASH (Figure 1D), consistent with hepatic IR
(% EGP suppression: 41.0 ± 4.3 vs. 70.2 ± 9.5%; p = 0.008).
These differences persisted even after removing patients with
type 2 diabetes (n = 6) from the NASH cohort (42.2 ± 5.6 vs.
70.2 ± 9.5%; p < 0.05).
Hepatic DNL
The percentage contribution of DNL to total endogenous
palmitate synthesis was variable across all individuals and
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A B
C D
Figure 1. Subjects with non-alcoholic steatohepatitis (NASH) have significant systemic, muscle and hepatic insulin resistance (IR). Circulating glucose
(A) and insulin (B) concentrations during the two-step hyperinsulinaemic euglycaemic clamp. The degree muscle and hepatic insulin sensitivity was
determined by glucose disposal (C) and suppression of hepatic glucose production (D), respectively. White bar = controls, black bar = NASH. *p < 0.05,
**p < 0.01, ***p < 0.001 versus controls.
although higher in NASH subjects compared with controls
[median 4.90 (IQR 3.9–5.6) vs. 2.79 (1.2–6.4); p = 0.16] this
did not reach significance.
Depot-speciﬁc adipose tissue IR
Circulating NEFA levels were not different between patients
with NASH and healthy controls (563 ± 33 vs. 465 ± 32 μmol/l;
p = 0.13; Figure 2A). However, taking into account fasting
hyperinsulinaemia in patients with NASH, the calculated
adipose IR index (fasting NEFA × fasting insulin [31]) was
significantly elevated (64.4 ± 9.1 vs. 20.5 ± 3.9 mmol/l pmol/l;
p = 0.0002) in patients with NASH. Insulin infusion signifi-
cantly suppressed circulating NEFAs in both NASH and control
subjects (p < 0.0001 vs. basal NEFA in each group; Figure 2A).
In order to determine insulin sensitivity, using regression
analysis, the insulin concentrations causing half-maximal sup-
pression of serum NEFA (INS- 1/2-max NEFA) were calculated
for each subject (Figure 2B). INS- 1/2-max NEFA was greater
than threefold higher in NASH subjects compared with the
controls (227 ± 35 vs. 65.2 ± 14 pmol/l; p = 0.0003) consistent
with adipose tissue IR. The significant difference in INS- 1/2-
max NEFA remained (195 ± 30 vs. 65.2 pmol/l; p = 0.0002)
after removing patients with type 2 diabetes (n = 7) from the
analysis.
Interstitial glycerol release assessed using microdialysis
was used as a direct measure of abdominal SAT function
(Figure 3A, B). In the fasting state, the rate of interstitial
glycerol release was not different in NASH subjects compared
with controls (383 ± 44 vs. 286 ± 40 μmol/l·h; p = 0.12). In
healthy controls, low-dose insulin infusion (20 mU/m2/min)
significantly suppressed the rate of interstitial glycerol release
(Basal: 286 ± 40 vs. low-dose insulin: 143 ± 18 μmol/l·h;
p < 0.001), whereas it did not suppress release in NASH subjects
(Basal: 383 ± 44 vs. low-dose insulin: 379 ± 43 μmol/l·h;
p > 0.05). High dose insulin (100 mU/m2/min) suppressed
glycerol release in both patients with NASH and in controls,
however, the rate of glycerol release remained significantly
higher in the NASH subjects compared with controls (261 ± 31
vs. 65.8 ± 14 μmol/l·h; p < 0.0001; Figure 3B). Furthermore,
the INS- 1/2-max glycerol was sixfold higher in the NASH
subjects compared with controls (p < 0.0001; Figure 4,
summary box). All of the above comparisons remained
significant after excluding subjects with type 2 diabetes (n = 7)
from the NASH cohort (Figure S2).
Serum Adipocytokines and Inﬂammatory Cytokines
Subjects with NASH had significantly higher fasting circulating
levels of TNF-α (p < 0.0001), hs-CRP (p < 0.05), IL-6
(p < 0.05) and CCL-2 (p < 0.05) than controls (Figure 5).
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A B
Figure 2. Subjects with non-alcoholic steatohepatitis (NASH) have significant global adipose tissue insulin resistance (IR). (A) Circulating non-esterified
fatty acid (NEFA) concentrations at basal and hyperinsulinaemic phases of euglycaemic clamp. (B) As a marker of global adipose tissue insulin resistance, the
concentration of circulating insulin concentrations (pmol/l) causing 1/2-maximal suppression of circulating NEFA was calculated. White bar = controls,
black bar = NASH. *p < 0.05, ***p < 0.001 versus controls. ++++p < 0.0001 versus basal phase. NS, non-significant.
A B
Figure 3. Non-alcoholic steatohepatitis (NASH) is associated with significant abdominal SAT IR. (A) SAT interstitial fluid concentrations of glycerol
during the 2-step hyperinsulinaemic euglycaemic clamp. (B) To determine the rate of lipolysis in subcutaneous adipose tissue (SAT) under basal
and hyperinsulinaemic conditions area under the curve (AUC) analysis was performed using the trapezoidal method for interstitial glycerol release.
Broken line/white bar = controls, solid line/black bar = NASH. ****p < 0.0001 versus controls; +++p < 0.001, ++++p < 0.0001 versus basal phase. NS,
non-significant.
Serum adiponectin levels (p = 0.001) were significantly lower
in NASH subjects, with a non-significant trend towards
higher circulating leptin compared with controls (p = 0.059).
The resultant leptin : adiponectin ratio was 2.5-fold higher
in NASH subjects than controls (3.22 ± 0.5 vs. 1.27 ± 0.4;
p = 0.0032). There were no significant differences in IL-
17, resistin and chemotactic cytokines CCL-3, CCL-4 and
CCL-5 (RANTES). With the exception of CCL-2 (p = 0.09),
differences in TNF-α (p < 0.0001), hs-CRP (p < 0.05), IL-6
(p < 0.05) and adiponectin remained significant after excluding
subjects with type 2 diabetes (n = 7) from the NASH cohort
(Figure S3).
Discussion
The data from this study have begun to address the tissue-
specific contributions make to global IR seen in patients with
NASH. Using novel techniques that have functional readouts of
insulin-regulated processes in a tissue-specific manner allows
an assessment of the contribution of the liver (EGP and DNL),
skeletal muscle (Gd), and adipose tissue (circulating NEFA
and adipose microdialysis) to systemic IR. By doing so, we
have not only demonstrated significant IR at the level of
the liver, muscle and adipose tissue, but also by measuring
depot-specific glycerol release, our study represents the first in
vivo description of dysfunctional abdominal SAT in patients
with NASH.
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Insulin conc. (pmol/L) ½-maximal
suppression of circulating NEFA
Insulin conc. (pmol/L) ½-maximal
suppression of scinterstitial adipose glycerol
Controls (n = 15) NASH (n = 16) p-value Controls (n = 15) p-value
65.2 +/-14.0 226.9 +/-35.2 0.0003 115.0 +/-12.3 682.6 +/-108.3 < 0.0001
NASH (n = 9)*
Figure 4. Subjects with non-alcoholic steatohepatitis (NASH) have a disproportionate higher degree of insulin resistance (IR) in subcutaneous adipose
tissue (SAT) (sixfold vs. controls) compared with whole-body adipose tissue (threefold vs. controls). Line graph representing the concentrations of
circulating non-esterified fatty acid (NEFA) (whole-body lipolysis) and interstitial fluid glycerol (SAT-specific lipolysis) in basal, low-dose and high-dose
insulin phases of the euglycaemic clamp. Black lines = NASH (mean ± s.e.), Grey line = control. Sold line = glycerol levels, broken line = NEFA levels.
We observed significant levels of hepatic and muscle IR in
NASH subjects, as represented by impaired insulin-mediated
suppression of hepatic glucose production and stimulated
muscle Gd (weight-adjusted), respectively. In keeping with
previous studies [6,13,32], the level of hepatic and muscle
IR remained significant when patients with type 2 diabetes
were removed from the analysis. Notably, we only saw a
non-significant trend towards higher levels of fasting DNL in
NASH subjects compared with healthy controls (4.9 vs. 2.8%;
p = 0.16). Even though the low levels of fasting DNL in healthy
subjects were consistent with the literature (i.e. <5.0%) [33],
our findings in NASH subjects were considerably lower (4.9
vs. 15–24%) than previously reported [11,34]. This might be
attributed to sampling DNL in the fasting state only, oral
administration of deuterated water (vs. intravenous deuterated
tripalmitate [11]) and/or the shorter duration of stable isotope
labelling compared with previous reports (14 vs. >96 h [11]).
Due to the nature of the stable isotopes incorporated as part
of the clamp and the high rates of labelled glucose infusions
required to maintain fasting glycaemia, we were unable to
assess the rates of DNL associated with hyperinsulinaemia. It
is important to note, however, that Donnelly et al. previously
reported that the majority of lipid accumulation in NASH was
attributed to adipose-derived NEFA (59%), rather than DNL
(26%) [11].
We demonstrated severe adipose tissue dysfunction in
patients with NASH using a variety of assessments including
adipose IR index, INS- 1/2-max NEFA, adipose tissue microdial-
ysis and circulating adipocytokines. The discrepancy between
high fasting leptin and low circulating levels of adiponectin
provided further evidence of abnormal adipose tissue func-
tion. Indeed, a growing body of evidence indicates that the
primary defect in NASH subjects occurs in adipose tissue [14],
from which triglyceride-derived toxic metabolites including
the NEFA pool, impair insulin signalling in both skeletal mus-
cle and liver tissue (‘lipotoxicity’). A vicious cycle of hepatic,
muscle and adipose tissue dysfunction ensues, leading to devel-
opment of a pathogenic circulating milieu of high levels of
insulin, glucose, NEFA and pro-inflammatory cytokines (e.g.
hsCRP, IL-6, TNF-α, and CCL-2), all of which were observed
in our patients with NASH.
Traditionally, VAT has been recognized as the major
contributor to hepatic IR and lipotoxicity [35], due to
its close proximity to the portal vein and concentration
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Figure 5. Subjects with non-alcoholic steatohepatitis (NASH) have significantly lower levels of fasting adiponectin (A) and higher levels of fasting
pro-inflammatory adipocytkines [(B) leptin, (C) high sensitivity C-reactive protein (hs-CRP), (D) tumour necrosis factor alpha (TNF-α), (E) interleukin-6
(IL-6) and (F) chemokine ligand-2 (CCL-2)/MCP-1]. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 versus controls.
of inflammatory mediators [16,17]. However, as VAT only
contributed to 15–20% of circulating NEFA pool [18,19],
researchers proposed that either VAT exerted its effects via
other non-NEFA factors including adipocytokines [35] or
that abdominal SAT plays an important role in lipotoxicity
[36]. Several studies have linked abdominal SAT with IR
using euglycaemic clamps in subjects with and without
metabolic syndrome [20–23], but our data is one of the
first to report depot-specific dysfunction in biopsy-proven
NASH subjects. Previous studies in NASH patients have
solely relied on circulating NEFA to provide estimates of
adipose IR [8,9,12,13,32], which are more reflective of whole-
body lipolysis, rather that depot-specific [37]. By directly
measuring interstitial fluid concentrations of glycerol, we
report novel insights into the degree of abdominal SAT IR
and lipolysis in patients with NASH. The greater magnitude
of resistance to the anti-lipolytic effect of insulin in SAT
(sixfold vs. controls) in comparison to whole-body adipose
(threefold vs. controls) in our study may well reflect depot-
specific IR, in which abdominal SAT is the major source
of lipotoxicity in NASH. Interestingly, using paired adipose
and liver biopsies from patients undergoing bariatric surgery
Tordjman et al. have recently shown that deep SAT (and
not superficial SAT) has an inflammatory profile (i.e. IL-6
gene, macrophage accumulation) similar to VAT in NASH
subjects [38].
One hypothesis is that abdominal SAT acts as ‘buffer’ for
excess calorific intake and triglyceride deposition. When SAT
fails to match the demand, as might be the case in NASH
subjects, adipose hypertrophy, inflammation (via macrophage
recruitment via CCL-2) and local IR sequentially develop. The
resultant localized excess NEFA, as reported here, can result in
an overspill of triglyceride-derived toxic metabolites into VAT
and subsequently the liver [39].
The role of ethnicity in adipose IR and NASH has recently
been investigated, in which Lomonaco et al. demonstrated
no difference in levels of IR (EGP, fasting NEFA) between
Hispanic and Caucasian cohorts with NASH, well-matched
for adiposity [32]. With the exception of two Italian studies
[7,12], very little data exists in well-characterized patients
with NASH of western European descent. Adipose IR index
in our UK cohort (9.3 mmol/l μU/l) was, however, similar
to that previously reported in NASH patients from southern
Europe and the USA (8.0–11.9 mmol/l μU/l), all of which
were 3–6.6 times higher than their respective healthy controls
[8,12,13].
Our study does have limitations, in particular, the metabolic
phenotype mismatch between the NASH and ‘healthy’ controls.
This remains a critical challenge in real-world research, due
to the high prevalence of obesity and metabolic syndrome
in patients with NASH at the time of first presentation.
Even though differences in adipose IR remained significant
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after exclusion of patients with diabetes (Figures S2, S3),
we were unable to extrapolate whether our findings were
independent of age and measures of adiposity. Gastaldelli et al.
have reported that whole-body lipolysis (using adipose-IR
index) in NASH is independent of obesity status (defined by
BMI) [13], but this requires validation with robust measures of
VAT and abdominal SAT mass/volume. In this study, we
were unable to directly compare SAT and VAT, as real-
time assessment of VAT function is not feasible in human
studies. The demonstration that SAT is the dominant source of
products of triglyceride hydrolysis in healthy humans [19]
and our finding of marked SAT IR may have significant
clinico-pathological implications in patients with NASH. This
suggests that it is not simply VAT accumulation that is
important in driving the pathological process. Lastly, the
cross-sectional design of our study did not allow a causal
relationship to be determined between dysfunctional SAT
and progressive liver disease. Previous longitudinal studies
(14 weeks) have shown that diet-induced decreases in MRI-
measured VAT correlate with improvements in hepatic lipid
content and markers of IR. However, no longitudinal studies
have investigated functional changes in VAT or SAT with
disease progression or regression after therapeutic intervention
[40].
In summary, our study highlights that patients with NASH
have marked adipose tissue dysfunction, alongside increased
hepatic and muscle IR. In particular, we have drawn attention
to the profound levels of IR and lipolysis in abdominal
SAT, which appears disproportionate to whole-body adipose.
Dysfunctional abdominal SAT likely plays a key role in NASH
lipotoxicity, rather than being just a bystander to VAT. Whether
this is indeed a tissue-mass effect remains to be investigated.
Future prospective studies that are sufficiently powered to
enable adjustment of metabolic confounders are now required
to investigate the relative contribution of SAT (vs. VAT) in
disease progression and the impact of novel interventions
in NASH.
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Figure S1. Schematic of the study design. All participants
underwent a two-step hyperinsulinaemic euglycaemic clamp
with stable isotope tracers (13C-glucose, deuterated water)
and adipose microdialysis to determine tissue-specific insulin
resistance.
Figure S2. Subjects with non-alcoholic steatohepatitis
(NASH) with and without type 2 diabetes had significant
abdominal subcutaneous adipose tissue (SAT) insulin resis-
tance (IR) compared with controls. (A) SAT interstitial fluid
concentrations of glycerol during the two-step hyperinsuli-
naemic euglycaemic clamp. (B) To determine the rate of
lipolysis in SAT under basal and hyperinsulinaemic conditions
area under the curve (AUC) analysis was performed using
the trapezoidal method for interstitial glycerol release. Bro-
ken line/white bar = controls, solid grey line/grey bar = NASH
without type 2 diabetes, sold black line/black bar = NASH
with type 2 diabetes. ****p < 0.0001 versus controls; +p < 0.05,
+++p < 0.001, ++++p < 0.0001 versus basal phase. NS, non-
significant.
Figure S3. Non-diabetic subjects with non-alcoholic
steatohepatitis (NASH) have significantly lower levels of
fasting adiponectin (A) and higher levels of fasting pro-
inflammatory adipocytkines [(C) high sensitivity C-reactive
protein (hs-CRP), (D) tumour necrosis factor alpha (TNF-α)
and (E) interleukin-6 (IL-6)]. Higher levels of (B) leptin and
(F) chemokine ligand-2 (CCL-2)/monocyte chemoattractant
protein-1 (MCP-1) were seen in non-diabetic subjects
with NASH, albeit not achieving significance. *p < 0.05,
****p < 0.0001 versus controls.
Appendix S1. Supplementary methods.
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